Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sino Biopharmaceutical ( (HK:1177) ) has issued an announcement.
Sino Biopharmaceutical Limited held its Annual General Meeting on June 10, 2025, where all proposed resolutions were approved by shareholders. Key resolutions included the adoption of the company’s financial statements for 2024, approval of a final dividend, re-election of directors, and authorization of the board to manage share capital and remuneration. The approval of these resolutions reflects strong shareholder support and positions the company for continued growth and stability in the biopharmaceutical sector.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. It focuses on the development, production, and sale of a wide range of pharmaceutical products, primarily targeting the Chinese market.
Average Trading Volume: 112,225,674
Technical Sentiment Signal: Buy
Current Market Cap: HK$81.38B
Learn more about 1177 stock on TipRanks’ Stock Analysis page.